midodrine has been researched along with Parkinson Disease in 9 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy and safety of sildenafil citrate (Viagra) in men with erectile dysfunction and parkinsonism due either to Parkinson's disease or multiple system atrophy." | 9.09 | Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. ( Brady, CM; Fowler, CJ; Hussain, IF; Mathias, CJ; Swinn, MJ, 2001) |
| "To assess the efficacy and safety of sildenafil citrate (Viagra) in men with erectile dysfunction and parkinsonism due either to Parkinson's disease or multiple system atrophy." | 5.09 | Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. ( Brady, CM; Fowler, CJ; Hussain, IF; Mathias, CJ; Swinn, MJ, 2001) |
| "Neurogenic orthostatic hypotension (nOH) is among the most debilitating nonmotor features of patients with Parkinson's disease (PD) and other synucleinopathies." | 2.66 | Clinical Trials for Neurogenic Orthostatic Hypotension: A Comprehensive Review of Endpoints, Pitfalls, and Challenges. ( Kaufmann, H; Palma, JA, 2020) |
| "Parkinson's disease is a cause of primary autonomic failure with involvement of the peripheral nervous system." | 2.42 | [Blood pressure disorders during idiopathic Parkinson's disease]. ( Senard, JM, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Palma, JA | 1 |
| Kaufmann, H | 1 |
| Goodman, BP | 2 |
| Claassen, D | 3 |
| Mehdirad, A | 1 |
| Kremens, D | 1 |
| Lew, M | 1 |
| Vernino, S | 1 |
| Asahina, M | 1 |
| Akaogi, Y | 1 |
| Yamanaka, Y | 1 |
| Koyama, Y | 1 |
| Hattori, T | 1 |
| Senard, JM | 1 |
| Jörg, J | 1 |
| Couban, S | 1 |
| Hussain, IF | 1 |
| Brady, CM | 1 |
| Swinn, MJ | 1 |
| Mathias, CJ | 1 |
| Fowler, CJ | 1 |
2 reviews available for midodrine and Parkinson Disease
| Article | Year |
|---|---|
Clinical Trials for Neurogenic Orthostatic Hypotension: A Comprehensive Review of Endpoints, Pitfalls, and Challenges.
Topics: Adrenergic alpha-1 Receptor Agonists; Antiparkinson Agents; Clinical Trials as Topic; Droxidopa; Hum | 2020 |
[Blood pressure disorders during idiopathic Parkinson's disease].
Topics: Adrenergic alpha-Agonists; Aged; Aging; Fludrocortisone; Humans; Hypotension, Orthostatic; Midodrine | 2003 |
1 trial available for midodrine and Parkinson Disease
| Article | Year |
|---|---|
Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension.
Topics: Aged; Blood Pressure; Cross-Over Studies; Diastole; Double-Blind Method; Ephedrine; Erectile Dysfunc | 2001 |
6 other studies available for midodrine and Parkinson Disease
| Article | Year |
|---|---|
Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
Topics: Aged; Antiparkinson Agents; Droxidopa; Female; Humans; Hypotension, Orthostatic; Midodrine; Parkinso | 2017 |
Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease.
Topics: Antiparkinson Agents; Droxidopa; Drug Therapy, Combination; Female; Fludrocortisone; Humans; Hypoten | 2017 |
Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus.
Topics: Aged; Antiparkinson Agents; Diabetes Mellitus, Type 2; Droxidopa; Female; Humans; Hypotension, Ortho | 2017 |
Differences in skin sympathetic involvements between two chronic autonomic disorders: multiple system atrophy and pure autonomic failure.
Topics: Aged; Autonomic Nervous System Diseases; Blood Flow Velocity; Blood Pressure; Female; Fludrocortison | 2009 |
[Therapeutic concept in Parkinson disease].
Topics: Adrenergic beta-Antagonists; Amantadine; Antidepressive Agents, Tricyclic; Benzodiazepines; Bromocri | 1983 |
Confusion of drug names signalled.
Topics: Aged; Aged, 80 and over; Amantadine; Humans; Male; Medication Errors; Midodrine; Parkinson Disease | 1995 |